Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Sep 20, 2023 9:10am
173 Views
Post# 35644968

RE:RE:Activist shareholder needed

RE:RE:Activist shareholder neededHoward's day job essentially pays him to participate in private placements, so we are not there yet. 

At the point of revenue stabilization where the company can afford a full time leader (shall I say leaders) that would be the period where a CEO could be appointed, and then that person could also appoint a full time management team. If that doesn't happen then, there are enough large shareholders around that will make sure it does happen.

I don't see that being super far out. We have already waited 15 months since the signing of the Allergan AbbVie agreement and suspect somewhere in the next 3-6 months we will see it hit shelves, with evidence of launch potentially peaking through prior. Every expert I have consulted with has said that 18 months is the median benchmark with some going quicker, others going a little later.

I think the next pipeline to get signed will be anti aging and that looks to be significantly bigger than the 1067 lineup. So we are getting closer but not there yet in my view. Unless they sign a new agreement in the next few months and/or receive a milestone payment for the launch part of the Allergan AbbVie agreement, then a small private placement will be required to bridge the interim.

Good luck. Pretty cheap shares when we look forward, if one is willing to put faith in AbbVie/Allergan to come through, because when/if that starts with royalty on gross sales price, the hindsight would look intriguing. 

All IFs and WHENs as we can all agree.


<< Previous
Bullboard Posts
Next >>